Pfizer Inc. (PFE)

My Top 3 Pharma Stocks

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect

Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).

What's Behind The Slump In Pfizer Stock?

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.

CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation

Wells Fargo CEO Charlie Scharf said AI is boosting productivity but will likely reduce workforce size. Pfizer CEO Albert Bourla warned China is closing the biotech and pharmaceutical patent gap rapidly and said the U.S. needs to focus on innovation.

Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?

Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.

Top Dividend Stocks Delivering Over 5% for True Financial Freedom

It is possible to achieve financial freedom through stock investing. If you pick the right companies, stay invested for the long term, and reinvest the dividends, you can build a solid portfolio for retirement.

3 Sizzling Ultra-High-Yield Stocks Under $50 With Upside Potential

Investors can have their higher yields and capital appreciation potential, too. But, of course, there are always added risks to consider, and when it comes to the hard-hit higher-yielders out there, the fundamentals and growth narrative have taken a turn for the worse.

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)

Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior market reactions. Upcoming Q3 earnings on November 4, 2025, are expected to provide clarity on oncology progress and the impact of the Trump administration's tariff decision, potentially leading to meaningful earnings revisions. Pfizer's deal with TrumpRx, offering drug discounts and committing $70 billion in U.S. manufacturing/R&D, reduces regulatory uncertainty and should attract new investors as guidance is met.

Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings

Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.

Life sciences sentiment rises as Pfizer deal eases tariff concerns

Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump Administration and Pfizer Inc (NYSE:PFE, ETR:PFE) has significantly eased the uncertainty around Most Favored Nation (MFN) tariffs on pharmaceuticals and related products, Citi analysts have highlighted. Under the deal announced late last month, Pfizer agreed to lower drug prices for Medicaid, sell discounted medicines directly to Americans, make significant investments in the US, and avoid tariffs for three years.

Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years

3 High-Yield Dividend Stocks to Buy in October

To investors, the stock market is considered one of if not the greatest ways to build wealth.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.

The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump

Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.

All Cap Investing With Kirk Spano

Kirk Spano runs Margin of Safety Investing and shares what this moment means for all cap investors. Stock picking and options strategies like covered calls and cash-secured puts to generate income and manage risk.

This 6.75%-Yielding Dividend Stock Can Gain 33%

Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration.

Pfizer Drug-Pricing Deal: More Upside For PFE Stock?

Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside potential.

Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.

3 Pharma Stocks Getting an Intraday Trump Bump

Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.

Pfizer found a way to boost its ailing stock — agree with Trump on drug pricing

Pfizer's stock surged after CEO Albert Bourla announces an agreement with the Trump administration aimed at lowering drug prices in the U.S. and removing tariff uncertainty.

What Pfizer's lower drug price agreement may mean for the company

CNBC's Angelica Peebles joins "The Exchange" to detail Pfizer's agreement with the Trump administration to voluntarily sell its medications at lower prices in the United States.

Pfizer CEO: 'The big winner of this deal clearly will be the American patient'

Pfizer CEO Albert Bourla, speaking in the Oval Office on Tuesday about the company's deal to lower drug prices, said the winner of the deal will "clearly will be the American patient." Bourla said the company satisfied all four of the requests President Trump outlined.

Top Stock Movers Now: Spotify, Pfizer, CoreWeave, Lamb Weston, and More

Major U.S. equities indexes edged lower Tuesday afternoon, as a potential government shutdown loomed. The Dow, S&P 500, and Nasdaq were all slightly lower.

US drugmakers rise after Trump announces Pfizer price cuts, promises more deals

Shares of Pfizer rose about 5% after U.S. President Donald Trump said on Tuesday the drugmaker will cut the price on all of its prescription drugs sold to the Medicaid insurance program and will introduce all new prescription drugs at a "most favored nation" price.